Janssen Pharmaceutical Companies of Johnson & Johnson and its partner Program for Appropriate Technology in Health (PATH) are exploring innovative applications of HIV medicines to improve treatment outcomes in hard-to-reach areas by finding ways to reduce the frequency of dosing.
In September 2013, Janssen R&D Ireland signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential PrEP against HIV infection.
Under the terms of the agreement, a Drug Development program of PATH, an international nonprofit organization that transforms global health through innovation, has the right to develop rilpivirine long-acting formulation as a possible new way to prevent HIV infection. PATH has the intent to conduct prophylaxis clinical trials in collaboration with partners including the HIV Prevention Trials Network. Following the completion of the clinical Phase 2 program, PATH and Janssen will evaluate entering into a late stage development agreement covering the use of rilpivirine as PrEP for uninfected individuals at high risk of acquiring HIV.
|Location||Central Africa, Eastern Africa, Zimbabwe, Zambia, Uganda, Togo, Tanzania, Swaziland, Sudan, Southern Sudan, South Africa, Sierra Leone, Seychelles, Senegal, Sao Tome and Principe, Rwanda, Nigeria, Niger, Namibia, Mozambique, Mauritius, Mauritania, Mali, Malawi, Madagascar, Liberia, Lesotho, Kenya, Guinea-Bissau, Guinea, Ghana, Gambia, Gabon, Ethiopia, Eritrea, Equatorial Guinea, Cote d Ivoire, Congo, The Republic of, Congo, The Democratic Republic of, Comoros, Chad, Central African Republic, Cape Verde, Cameroon, Burundi, Burkina Faso, Botswana, Benin, Angola, West Africa, Southern Africa|